Serina Therapeutics, Inc. (SER) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: March 26, 2024
Company: Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.)
Event: Completion of a reverse merger with Serina Therapeutics, Inc. (Alabama) and subsequent name change.
Business Description: The Company is now a clinical-stage biotechnology company developing Serina's drug product candidates. Headquarters are located in Huntsville, Alabama.
Accounting Treatment: The transaction was treated as a reverse recapitalization; Serina is the accounting acquirer.
Key Financial Metrics and Capital Structure
Debt Obligations:
- 2022 Convertible Note: AgeX drew an additional $2.4 million, bringing the aggregate principal to $9.3 million. Accrued and unpaid origination fees are approximately $561,000.
- 2023 Convertible Note: Approximately $692,800 in accrued and unpaid origination fees remain outstanding.
- Restructuring: Obligations under these notes were transferred to a subsidiary, UniverXome Bioengineering, Inc., releasing AgeX (now Serina) from direct liability, subject to a claims reserve.
- Shares Issued: 5,913,277 shares of common stock issued to Serina stockholders at an exchange ratio of 0.97682654.
- Post-Merger Ownership: Prior Serina equityholders own approximately 75% of the Company; prior AgeX equityholders own approximately 25% (fully diluted, excluding warrants).
- Major Stockholder: Juvenescence Limited and affiliates beneficially own approximately 32.6% of the outstanding shares.
- The Convertible Notes Agreement included a mechanism to ensure the Company had $500,000 of immediately spendable non-restricted cash net of liabilities at closing.
- The filing text does not provide specific revenue, profit, or cash flow figures for the current period. Audited financial statements for Serina for years ended Dec 31, 2023 and 2022 are referenced in Exhibit 99.2.
Material Changes vs. Prior Period
- Corporate Identity: The registrant changed its name from "AgeX Therapeutics, Inc." to "Serina Therapeutics, Inc."
- Trading Symbol: Common stock began trading on NYSE American under the symbol "SER" on March 27, 2024 (previously "AGE").
- Leadership Changes:
- Interim CEO: Steven Ledger appointed Interim CEO; Dr. Joanne M. Hackett terminated as Interim CEO.
- Board Composition: Board reconstituted with J. Milton Harris as Chairman. Dr. Hackett and Dr. Jean-Christophe Renondin resigned.
- Executive Team: Randall Moreadith appointed Chief Scientific Officer; Tacey Viegas appointed Chief Operating Officer; Andrea Park appointed Interim CFO.
- Debt Structure: Significant debt obligations were moved to a subsidiary (UniverXome) to facilitate the merger closing conditions.
Guidance, Outlook, and Risks
Outlook: The Company is focused on advancing Serina's drug product candidates. Management intends to recruit a permanent CEO and CFO.
Risks and Contingencies:
- Financing: Risks regarding the ability to secure additional financing to fund operations and clinical trials.
- Development: Risks associated with clinical trial outcomes, regulatory approvals, and commercialization of product candidates.
- Market: Risks related to the Company's ability to remain listed on NYSE American and potential dilution from warrant exercises.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from projections due to uncertainties in the biotechnology sector.
Investor Verification Checklist
- Debt Transfer Validity: Verify the legal release of AgeX/Serina from the $9.3M+ convertible note obligations and the solvency of the subsidiary (UniverXome) assuming the debt.
- Cash Runway: Review Exhibit 99.4 (MD&A) and Exhibit 99.2 (Audited Financials) to confirm the $500,000 closing cash condition was met and assess total cash on hand post-merger.
- Warrant Dilution: Analyze the impact of Juvenescence's warrants (included in their 32.6% beneficial ownership) on future share count and dilution.
- Leadership Stability: Monitor the timeline for the appointment of a permanent CEO and CFO, as current leadership is interim.
- Pro Forma Financials: Review Exhibit 99.3 for unaudited pro forma condensed combined financial information to understand the combined entity's financial position.